Profile

AIKATERINI SYRIGOU

ALLERGOLOGIST

3RD DEPARTMENT OF INTERNAL MEDICINE, SCHOOL OF MEDICINE,
NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS
  1. General
  • Education & Academic Titles

    • 30.06.1988: Medical School, University of Athens
    • 02.01.1996: Specialty of Allergist

  • Doctoral Thesis

    20.03.2002: PhD, from the University of Athens Medical School with grade «Excellent»

  • Professional Experience

    • 02.2008 – 04.2023: Chairman in N.H.S, Allergology Department, General Hospital «SOTIRIA», Athens, Greece
    • Present Position (from 04.2023): Assosiate Professor, 3rd Department of Internal Medicine School of Medicine, National and Kapodistrian University of Athens

  • Clinical Interest

    • Drug allergy
    • Asthma
    • Food allergy 
    • Anaphylaxis

  • Awards & Distinctions

    SCHOLARSHIPS

    • 1997-1998: Scholarship of the "A.G.Leventis" Foundation for her  postgraduate training at the IMPERIAL COLLEGE - ROYAL BROMPTONHOSPITAL Lung and Heath institution LONDON UK
    • 1997: Scholarship from the British Society of Allergy and Clinical Immunology BSACI
    • 1996: Fellowship from the European Association of Allergy and Clinical Immunology EAACI
    • 1987: Scholarship of the School of Medicine of the University of Athens to the five students with the highest marks of the year

    AWARDS

    • 1994: 3rd  Prize, 32nd Panhellenic Pediatric Congress
    • 2002: 1st Prize, 40th Panhellenic Pediatric Congress
    • 2016: First Prize for Best Paper, 11th Panhellenic Allergy Congress
    • 2018: First Prize for Best Paper, 12th Panhellenic Allergy Congress
    • 2019: First Prize for Free Communications, State of the Art
    • 2019: Best Oral Communication Award, 13th Panhellenic Allergy Conference
    • 2020: Best Oral Communication Award, 14th Panhellenic Allergy Conference
    • 2022: 3rd Prize for Best Oral Communication, 16th Panhellenic Allergy Congress
    • 2023: 1st Prize for Best Communication,17th Panhellenic Allergy Congress

     

  • Recent Publications

    • Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis.
      Stefanou MI, Palaiodimou L, Theodorou A, Christodoulou MV, Tzartos JS, Tzanetakos D, Kitsos D, Chondrogianni M, Zouvelou V, Dardiotis E, Tzavellas E, Syrigou E, Benetou V, Paraskevas GP, 
      Tsiodras S, Tsivgoulis G, Giannopoulos S.
      Mult Scler. 2023Apr;29(4-5):585-594. 
      doi: 10.1177/13524585221150881. Epub 2023 Feb 1. PMID: 36722184
    • Assessment of seroconversion after SARS-CoV2 vaccination in patients with lung cancer
      I.Trontzas *, I.Vathiotis, C.Economidou,I. Petridou, G. Gomatou, M. Grammoustianou, I. Tsamis,N. Syrigos, M. Anagnostakis, E. Fyta, V. Sakka,G. Poulakou, E. Kotteas, E Syrigou
      Vaccines (Basel).2022Apr 15;10(4):618. 
      doi:10.3390/vaccines10040618. PMID: 35455367; PMCID: PMC9031406.
    • Significant Increase in Blood Pressure Following BNT162b2 mRNA
      COVID-19 Vaccination among Healthcare Workers: A Rare Event. Vaccines (Basel).
      Syrigos N, Kollias A, Grapsa D, Fyta E, Kyriakoulis KG, Vathiotis I, Kotteas E, Syrigou E
      Vaccines (Basel). 2022May 10;10(5):745. 
      doi: 10.3390/vaccines10050745. PMID: 35632501; PMCID: PMC9143263.
    • Efficacy of a Quail Eggs-BasedDietarySupplementforAllergicRhinitis:Resultsofa Single-Arm Trial.
      SyrigouE,PsarrosF,MakrisM,GrapsaD,SyrigosK.
      JDietSuppl.2019Nov25:1-14.doi:10.1080/19390211.2019.1694121.
    • Treatmentresponsetoomalizumabinpatientswithrefractorychronicspontaneous urticaria.
      SyrigosN,GrapsaD,ZandeM,TziotouM,SyrigouE.
      IntJDermatol.2018Apr;57(4):417-422.doi:10.1111/ijd.13935.

  • Membership in Societies and Editorial Boards
    • American Academy of Allergy Asthma and Ιmmunology (AAAAI)
    • European Academy of Allergology and Clinical Immunology (EAACI)
    • European Respiratory Society (ERS)
    • British Society for Allergy & Clinical Immunology (BSACI)
    • International Association for Aerobiology (IAA)
    • Hellenic Society of Allergy and Clinical Immunology (HSACI)
    • Hellenic Society of Paediatrics
    • Hellenic Society of Adolescent Medicine
    • From 01/2013 to 12/2019: She was a member of the editorial board of the Greek Journal of the Hellenic Society of Allergy and Clinical Immunology (HSACI) entitled: "Hellenic Allergy and Clinical Immunology"
    • From January 2020 until today she has been the editor-in-chief of the same journal
  • Research

    Both as Director and as Associate Professor she developed a strong activity in Clinical Research. She participated as Principal Investigator in Phase II and III Clinical Trials supported by the pharmaceutical industry, by independent institutions (CIOs) and in Investigator Initiated Studies

    • Menarche and fat intake with diet. Duration of participation 3 years .Institution: KESY (Funded research). Her Doctoral Thesis
    • Evaluation of sublingual immunotherapy in children with olive allergy. Duration of participation 2 years
    • The therapeutic effect of salmeterol in children with severe asthma. Duration of participation 1 year
    • Double-blind,Placebo-controlledDose-findingStudywithCYT003-QbG10inAdultpatients with Rhinoconjuctivitis due to House Dust Mite Allergy
    • ClinicalTrialProtocolCYT003-QbG1009(PhaseIIstudy)
    • FASTproject(FoodAllergySpecificImmunotherapy),7thFrameworkProgramme(FP7). Funded by the European Union, Health-2007-1.4.3: Immunotherapy of human food allergies, EU-Grant 201871.
    • REGINAcodeC1GE025AGR03/20-1-2010
    • “CHOICE”12/2014.:Acrosssectional epidemiological studyofallergicrhinitisinroutine clinical practice in Greece
    • “AWARE-CIGE025E”:Chronicurticarianon-interventional studytocollectreallifeclinical data on the impact of therapy, the diagnosis and management of chronic urticaria in patients refractory to at least one course of H1-antihistamine therapy
    • QGE031/LigelizumabClinicalTrialProtocol(CQGE031C2201)
    • A multicenter, randomised, double-blind, placebo and active-controlled phase ΙΙ dose- findingstudy ofQGE031asadd-ontherapytoinvestigate th eefficacy and safety in patients with Chronic Spontaneous Urticaria (CSU)
    • Μελέτη FAST2015.FAST-FoodAllergySpecificImmunotherapy
    • A multinational phase IIb study to investigate the efficacy and safety of subcutaneous immunotherapy with a modified fish-parvalbumin given in single rising and maintenance doses to subjects allergic to fish
    • Principal–investigatorinthecompletedstudyGQAW039A2314
    • Principal–investigatorintheongoingstudy CQGE031C2302
    • Principal–investigatorintheongoingstudyCQAW039A2315